ASPIRE-FTD Phase 1/2 Clinical Trial Opens in the U.S. at The Ohio State University Wexner Medical Center
AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101
AviadoBio Announces Presentation of Safety and Biodistribution Data of AVB-101
AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations
AviadoBio Signs Exclusive License Agreement with Neurgain Technologies for Novel Gene Therapy Spinal Delivery Technology
AviadoBio Announces Appointment of Jeff Goater as Chair of the Board of Directors
London, UK; October 4, 2022 — AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, today announced the promotions of Graeme Fielder, Ph.D. to Chief Operating Officer and Alex Bloom, Ph.D. to Chief Technical Officer.
London, UK; Tuesday, August 2, 2022 — AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, today announced the appointment of David Cooper, MD, MBA, as Chief Medical Officer (CMO).
AviadoBio Presents Preclinical Data at ASGCT 2022 Demonstrating that AVB-101 Represents a Novel and Promising Approach to the Treatment of Frontotemporal Dementia Intrathalamic...